research
A Brain-Cancer Resistance Route Meets a New Inhibitor
Cell experiments found that blocking neuronal nitric oxide synthase could resensitize temozolomide-resistant glioblastoma models.
Summary
Cell experiments found that blocking neuronal nitric oxide synthase could resensitize temozolomide-resistant glioblastoma models.
Hebrew University researchers tested a neuronal nitric oxide synthase inhibitor against glioblastoma cells that had become resistant to temozolomide. The experimental approach targeted a survival pathway associated with drug resistance and restored treatment sensitivity in the reported cell models. The result identifies a candidate combination strategy for further study. It remains preclinical work in cells and does not show safety or benefit in patients.
Why it matters
Cell experiments found that blocking neuronal nitric oxide synthase could resensitize temozolomide-resistant glioblastoma models.
Limits and context
- It remains preclinical work in cells and does not show safety or benefit in patients.
Key claims
Cell experiments found that blocking neuronal nitric oxide synthase could resensitize temozolomide-resistant glioblastoma models.
Qualification: It remains preclinical work in cells and does not show safety or benefit in patients.
Evidence: source-2026-07-15-011
Sources
- Hebrew University via EurekAlert: Experimental approach to drug-resistant brain cancerHebrew University via EurekAlert · official announcement
Corrections
No corrections have been recorded for this story.